Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 2
1998 1
2004 1
2006 1
2007 2
2008 1
2009 4
2010 1
2011 1
2012 2
2013 5
2014 3
2015 5
2016 5
2017 6
2018 8
2019 21
2020 23
2021 17
2022 17
2023 13
2024 23
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJL. Wheeler DC, et al. Among authors: khullar d. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234. Nephrol Dial Transplant. 2020. PMID: 32862232 Free PMC article. Clinical Trial.
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Yu MK, Vart P, Jongs N, Correa-Rotter R, Rossing P, McMurray JJV, Hou FF, Douthat W, Khullar D, Langkilde AM, Wheeler DC, Heerspink HJL, Chertow GM. Yu MK, et al. Among authors: khullar d. J Gen Intern Med. 2024 May;39(6):921-930. doi: 10.1007/s11606-023-08397-9. Epub 2023 Dec 14. J Gen Intern Med. 2024. PMID: 38097862 Free PMC article. Clinical Trial.
Patient-Centered Performance Metrics-Reply.
Khullar D, Wolfson D, Casalino LP. Khullar D, et al. JAMA. 2019 May 14;321(18):1829-1830. doi: 10.1001/jama.2019.2080. JAMA. 2019. PMID: 31087020 No abstract available.
Misinformation, Identity, and the Basis of Belief.
Khullar D, Young DG. Khullar D, et al. Ann Intern Med. 2025 Mar;178(3):436-438. doi: 10.7326/ANNALS-24-02844. Epub 2024 Dec 31. Ann Intern Med. 2025. PMID: 39745497 No abstract available.
Finerenone: Will It Be a Game-changer?
Khullar D, Gupta AK, Singh K. Khullar D, et al. Card Fail Rev. 2024 Dec 23;10:e19. doi: 10.15420/cfr.2024.11. eCollection 2024. Card Fail Rev. 2024. PMID: 39872849 Free PMC article. Review.
C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation.
Heidenreich K, Goel D, Priyamvada PS, Kulkarni S, Chakurkar V, Khullar D, Singh R, Bale C, Zipfel PF. Heidenreich K, et al. Among authors: khullar d. Front Nephrol. 2024 Oct 29;4:1460146. doi: 10.3389/fneph.2024.1460146. eCollection 2024. Front Nephrol. 2024. PMID: 39534179 Free PMC article. Review.
"Natural Experiments" in Health Care Research.
Khullar D, Jena AB. Khullar D, et al. JAMA Health Forum. 2021 Jun 4;2(6):e210290. doi: 10.1001/jamahealthforum.2021.0290. JAMA Health Forum. 2021. PMID: 36218753 Free article. No abstract available.
159 results